<DOC>
	<DOCNO>NCT00076232</DOCNO>
	<brief_summary>Genital herpes ( HSV-2 ) common cause genital sore worldwide , presence genital sores significant risk factor become infected HIV . This study test effectiveness twice-daily dose acyclovir , commonly prescribe anti-herpes drug , prevent HIV infection HSV-2 infected woman sleep men ( WSM ) men sleep men ( MSM ) . Study hypothesis : Given genital herpes significant risk factor HIV acquisition , twice-daily HSV-2 suppressive therapy - 400 mg acyclovir - prevent HIV infection among high risk , HSV-2 seropositive WSM MSM .</brief_summary>
	<brief_title>A Study Acyclovir Help Prevent HIV Infection People With Genital Herpes</brief_title>
	<detailed_description>Many study show prior HSV-2 infection associate increase risk HIV infection . Acyclovir widely study clinically utilized antiviral suppression HSV-2 infection . This study evaluate efficacy twice-daily dose acyclovir prevent HIV infection WSM MSM genital herpes . For study , WSM enrol Lusaka , Zambia ; Harare , Zimbabwe ; Johannesburg , South Africa ; MSM enrol Lima Pucallpa , Peru ; Seattle , Washington , USA ; New York City , New York , USA ; San Francisco , California , USA . Participants enrol 12 month study randomly assign one two study arm . The first arm receive 400 mg acyclovir twice daily ; second arm receive placebo . Follow-up visit occur monthly . Participants test STDs , include HIV syphilis , visit treat necessary ; participant also give adherence condom counseling , risk behavior sexual history questionnaire , genital symptom questionnaire study visit . Medical history assess participant undergo blood work Months 3 , 6 , 9 , 12 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria For All Participants : HIVuninfected HSV2 infect Plans stay area duration study participation Willing able provide consent , undergo clinical evaluation , take study drug , adhere followup schedule , provide adequate locator information Inclusion Criteria MSM : At least 1 episode anal intercourse another man within 6 month study entry Inclusion Criteria WSM : At least 1 episode unprotected vaginal sex within 6 month study entry Exclusion Criteria For All Participants : Current enrollment another HIV vaccine prevention trial History adverse reaction acyclovir Current plan use famiciclovir , valacyclovir , acyclovir genital HSV . Use shortcourse antiviral therapy herpes zoster enrollment allow . Known plan travel away study site 2 month Exclusion Criteria MSM : In mutually monogamous relationship HIV uninfected partner throughout past 2 year Reported sex birth female Exclusion Criteria WSM : Pregnancy screen enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HIV Seronegativity</keyword>
</DOC>